Guaifenesin Price Index: Trend, Chart, Market Analysis and Forecast 2026

According to ChemAnalyst, The global Guaifenesin Prices witnessed an upward trend during the second quarter of 2026, with North America and Asia-Pacific (APAC) recording notable quarter-over-quarter increases. Higher freight charges, elevated transportation expenses, and persistent logistical challenges influenced the pricing environment, increasing the overall cost of moving the pharmaceutical ingredient across international supply chains. In Europe, particularly Germany, the market also experienced sustained upward pressure as higher freight and insurance costs affected imported material and landed prices.

Guaifenesin is an expectorant widely used in cough and cold medications to help loosen mucus and support its removal from the respiratory tract. It is incorporated into a variety of pharmaceutical formulations, including syrups, tablets, capsules, and combination cold remedies. As a result, demand for guaifenesin is closely connected to pharmaceutical manufacturing activity, seasonal respiratory illness patterns, consumer healthcare spending, and procurement decisions by drug manufacturers.

During Q2 2026, the primary factor influencing the Guaifenesin Price Trend was the rising cost of logistics rather than a clearly established change in underlying consumption. Increased freight rates, container availability constraints, longer transit times, and higher insurance expenses affected the cost of transporting pharmaceutical ingredients between manufacturing centres and destination markets. These developments placed pressure on importers and distributors, particularly those dependent on internationally sourced material.

For pharmaceutical buyers, the quarter highlighted the importance of evaluating freight exposure alongside supplier quotations. Although the reported regional prices reflected different market conditions, logistics remained a common factor influencing the overall direction of the market.

Guaifenesin Prices in North America

In the United States, the Guaifenesin Price Index increased by 7.719% quarter-over-quarter in Q2 2026, while the average quarterly price stood at approximately USD 6,917/MT. The upward movement was primarily attributed to higher freight costs, which raised the expenses associated with transporting guaifenesin and other pharmaceutical ingredients through international and domestic distribution networks.

Freight-related cost inflation affected the delivered cost of pharmaceutical raw materials, particularly for buyers relying on imported supplies. When transportation expenses increase, importers may face higher landed costs even when the underlying supplier price remains relatively stable. These additional costs can influence distributor margins, inventory valuation, and the pricing of material supplied to pharmaceutical formulation manufacturers.

Get Real Time Online for Guaifenesin Prices: https://www.chemanalyst.com/Pricing-data/guaifenesin-2551

The US pharmaceutical supply chain depends on coordinated procurement, international shipping, warehousing, and distribution. Any disruption in these activities can increase the total cost of obtaining active pharmaceutical ingredients and pharmaceutical intermediates. During the quarter, elevated freight expenses added pressure to procurement budgets and encouraged buyers to review supplier contracts and delivery arrangements.

Demand from manufacturers of cough syrups, expectorant tablets, and combination cold medications continued to provide an important underlying market consideration. Guaifenesin is used in both prescription and over-the-counter formulations, making it relevant to established respiratory healthcare product lines. Nevertheless, the available Q2 pricing information indicates that transportation expenses were the principal reported driver of the quarterly increase.

Seasonality also remains an important consideration for the US market. Respiratory medication demand can vary throughout the year, with colder weather and seasonal illnesses often influencing purchasing patterns. Pharmaceutical companies may adjust their inventory positions ahead of anticipated demand, while distributors must balance storage costs against the risk of supply shortages. However, the reported quarterly increase should not be attributed to seasonal demand alone.

The increase of 7.719% indicates that buyers experienced a meaningful rise in the average cost of guaifenesin during the quarter. Procurement teams may respond by comparing delivered prices across suppliers, consolidating shipments where practical, and negotiating more predictable freight arrangements. Maintaining adequate inventory coverage can also help reduce exposure to sudden transportation disruptions.

Looking ahead, the North American Guaifenesin Price Trend will depend on the evolution of international freight rates, shipping capacity, supplier availability, and pharmaceutical purchasing activity. If logistics expenses remain elevated, delivered prices could continue to face upward pressure. Conversely, improved container availability and more efficient shipping schedules could moderate landed-cost increases.

Guaifenesin Prices in APAC

The Asia-Pacific market also recorded an upward movement during Q2 2026. In China, the Guaifenesin Price Index rose by 7.44% quarter-over-quarter, while the average price reached approximately USD 6,845.33/MT. Higher freight expenses were the principal reported factor supporting the increase, demonstrating the continued influence of transportation costs on regional pharmaceutical ingredient pricing.

China occupies an important position in the international pharmaceutical manufacturing and chemical supply chain. Its manufacturing ecosystem supports the production and distribution of pharmaceutical ingredients, intermediates, and finished medicines. Consequently, developments affecting export logistics, shipping availability, and distribution expenses can influence prices quoted to domestic and international buyers.

During the quarter, freight pressures contributed to higher costs across the supply chain. Exporters and distributors faced the challenge of managing shipping expenses while maintaining competitive quotations for overseas customers. Where transportation costs increased, suppliers could experience pressure on margins or seek to incorporate some of the additional expenses into selling prices, depending on contractual arrangements and competitive conditions.

The Chinese Guaifenesin Price Trend also reflects the interaction between manufacturing economics and export-oriented supply chains. Pharmaceutical ingredient producers must manage production costs, quality-control requirements, packaging, storage, and transportation. Although freight was the principal driver identified for Q2, the extent to which these other factors influenced individual transactions may have varied between suppliers.

Demand from pharmaceutical manufacturers remains an important consideration for the APAC market. Guaifenesin is used in cough and cold formulations, including oral liquids and solid-dose products. Procurement activity can therefore depend on domestic medicine consumption, export orders for finished pharmaceutical products, and the production schedules of formulation manufacturers.

However, the reported quarterly price increase does not independently establish that pharmaceutical consumption strengthened during the period. Instead, the available pricing information points primarily to logistics-related cost pressure. Separating changes in supplier prices from changes in freight charges is essential for understanding the underlying market direction.

For buyers in China and other APAC markets, transportation planning can play a significant role in procurement efficiency. Companies may benefit from evaluating alternative shipping routes, consolidating orders, coordinating delivery schedules, and negotiating freight terms with suppliers. Buyers serving multiple export destinations may also need to account for differences in transit times, port handling charges, and destination-specific delivery requirements.

The outlook for Guaifenesin Prices in APAC will depend on freight market conditions, manufacturing capacity, export demand, and the availability of shipping containers. A reduction in transportation costs could ease upward pressure, while persistent logistical constraints could continue to influence export quotations and delivered prices.

Guaifenesin Prices in Europe

The European guaifenesin market maintained a firm upward trend during Q2 2026, with Germany experiencing pressure from elevated freight and insurance expenses on Europe–Asia shipping routes. Unlike the US and Chinese markets, for which specific quarterly percentage increases and average prices were provided, the available German market information identifies the direction of the trend and its main logistical drivers without specifying an exact percentage change or average quarterly price.

Germany is an important pharmaceutical manufacturing and distribution market, supported by established medicine producers, contract manufacturers, wholesalers, and healthcare supply networks. Companies operating in the country depend on reliable access to pharmaceutical ingredients that meet applicable quality and regulatory requirements. For imported materials, the final procurement cost can be influenced by the supplier's quotation as well as shipping, insurance, customs-related charges where applicable, handling, and inland transportation.

During the quarter, elevated freight expenses on Europe–Asia lanes increased the cost pressure associated with moving pharmaceutical ingredients between manufacturing locations and European destinations. Container imbalances and longer transit times further complicated logistics planning. These conditions can increase the cost of securing transportation capacity and extend the period between order placement and material receipt.

Insurance costs also contributed to the broader landed-cost environment. Shipping insurance expenses may rise when transportation risks, route uncertainty, or other market conditions change. For importers handling pharmaceutical ingredients, these expenses add to the overall cost of bringing products into the market and may affect supplier comparisons.

Longer transit times can have consequences beyond the freight invoice itself. When shipments take more time to arrive, pharmaceutical manufacturers may need to maintain larger safety stocks, adjust production schedules, or place replenishment orders earlier than usual. These responses can increase working-capital requirements and warehouse expenses, particularly for companies managing several imported ingredients simultaneously.

The German Guaifenesin Price Trend therefore reflected a combination of elevated transportation and insurance costs, container availability challenges, and extended shipping schedules. These factors influenced the landed cost of material and complicated procurement decisions for buyers dependent on international supply routes.

Demand from manufacturers of respiratory medicines remains a relevant market consideration. Guaifenesin is used in expectorant formulations and combination cough and cold products, supporting its role in pharmaceutical ingredient procurement. Nevertheless, the available information does not establish a specific increase in German consumption during Q2 2026. The upward pricing trend is more directly associated with logistics-related pressures.

European buyers can manage this exposure by reviewing delivery terms, evaluating supplier diversification, and incorporating realistic lead times into inventory planning. Comparing offers on a landed-cost basis rather than relying exclusively on ex-works or FOB quotations can provide a clearer picture of the total procurement expense.

Going forward, the European Guaifenesin Price Trend will depend on the cost and reliability of Europe–Asia transportation, insurance premiums, shipping schedules, and the availability of alternative supply arrangements. Improved container balance and shorter transit times could reduce pressure on landed costs, while continued disruption could sustain the upward trend.

Key Factors Influencing Guaifenesin Prices in Q2 2026

Several interconnected factors shaped the global Guaifenesin Prices market during the second quarter of 2026.

Rising Freight and Transportation Costs

Freight expenses were the principal reported driver of price increases in the United States and China and an important factor in Germany. Higher shipping costs raise the total expense of moving pharmaceutical ingredients from manufacturing centres to end markets. Their influence is especially important for buyers that rely on imported supplies and long-distance distribution.

Container Availability and Shipping Imbalances

Uneven container availability can make it more difficult to secure transportation capacity at predictable rates. When equipment is concentrated in certain locations or shipping schedules become less reliable, exporters and importers may face higher logistics costs. These conditions can affect delivery planning and the consistency of supplier quotations.

Longer Transit Times

Extended transit times can increase inventory requirements and complicate production scheduling. Pharmaceutical manufacturers may need to order material earlier, maintain additional safety stocks, or adjust procurement cycles to protect production continuity. These measures can raise indirect costs even when the product's quoted price changes only modestly.

Insurance and Landed-Cost Pressures

Insurance expenses contributed to the upward pricing environment in Europe. More broadly, the landed cost of guaifenesin includes several components beyond the initial supplier quotation. Freight, insurance, handling, and applicable import-related charges can all affect the final amount paid by buyers.

Pharmaceutical Manufacturing and Procurement Demand

Demand from manufacturers of cough and cold medicines provides an underlying source of market activity. Production schedules, customer orders, inventory strategies, and seasonal purchasing can influence procurement volumes. However, the available Q2 2026 information identifies logistics rather than a demonstrated surge in end-user demand as the principal driver of the reported price increases.

Guaifenesin Price Trend: Regional Comparison

The second quarter of 2026 showed a broadly upward price trend across the three reported markets, although the level of available data differed by region.

The United States recorded a slightly higher percentage increase than China, with a difference of 0.279 percentage points. This comparison indicates that both markets experienced substantial upward movement during the quarter, although their average prices and commercial conditions differed.

The US average price was approximately USD 71.67/MT higher than the Chinese average. This difference should not automatically be interpreted as a direct measure of regional profitability or supplier competitiveness. Freight terms, product specifications, transaction timing, delivery conditions, and the basis of quotation can influence regional price comparisons.

Germany's trend reinforces the broader observation that international logistics can affect pharmaceutical ingredient procurement even when a precise regional price figure is unavailable. A complete comparison would require consistent data covering the same product grade, period, currency, quantity, and delivery basis.

Book A Demo for Guaifenesin Prices: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Guaifenesin

Impact of Guaifenesin Prices on Pharmaceutical Manufacturers

Changes in Guaifenesin Prices can influence procurement budgets, manufacturing costs, and supply-chain planning for pharmaceutical companies. Although guaifenesin represents only one component of many finished medicines, changes in its cost can affect product economics when combined with increases in packaging, transportation, labour, and other ingredients.

Manufacturers operating under fixed-price supply agreements may find it difficult to pass on unexpected procurement increases immediately. This can place temporary pressure on product margins, especially when contracts limit the frequency or extent of price revisions. Companies purchasing on shorter contract cycles may be able to adjust more quickly, although they may also face greater exposure to spot-market fluctuations.

Distributors and wholesalers must also consider the impact of changing acquisition costs on inventory valuation and replenishment decisions. Buying additional material ahead of anticipated increases can reduce the risk of higher replacement costs, but excessive stockholding can tie up working capital and introduce storage or expiry-related risks.

Effective procurement therefore requires a balance between cost management and supply continuity. Pharmaceutical companies can improve resilience by monitoring supplier performance, comparing total delivered costs, and maintaining appropriate inventory buffers based on actual consumption and lead times.

Quality assurance remains essential throughout this process. Any decision to diversify sourcing or change suppliers should account for applicable pharmaceutical quality standards, documentation requirements, and regulatory obligations. A lower quotation is not necessarily the most economical option if it introduces quality concerns or increases the risk of delayed production.

Guaifenesin Prices Forecast: Outlook for the Coming Quarters

The outlook for Guaifenesin Prices after Q2 2026 will depend substantially on whether freight and insurance costs remain elevated or begin to ease. The available information supports a logistics-focused assessment but is insufficient to establish a precise numerical forecast for the remainder of 2026.

If shipping costs remain high, buyers in North America, APAC, and Europe could continue to experience pressure on delivered prices. Persistent container imbalances, extended transit times, and higher insurance expenses may increase procurement costs and encourage suppliers to review quotations.

Alternatively, improved shipping availability, more predictable transit schedules, and lower freight charges could moderate the landed cost of guaifenesin. In such circumstances, competitive supplier offers may become easier to secure, although the speed of any price adjustment would depend on contract structures and inventory positions.

Demand for respiratory medicines will remain an important variable. Changes in seasonal illness patterns, pharmaceutical production schedules, and inventory replenishment can influence purchasing volumes. Developments in manufacturing capacity and supplier competition may also affect regional pricing, but their precise impact cannot be quantified from the available Q2 data.

For procurement teams, the most useful approach is to monitor freight quotations alongside supplier prices, compare offers on equivalent commercial terms, and track lead-time changes across major sourcing routes. Scenario-based budgeting can help manufacturers prepare for both continued cost increases and potential market stabilisation.

Conclusion

The global Guaifenesin Prices market recorded an upward trend in Q2 2026, primarily due to elevated logistics costs. The US price index rose by 7.719% to an average of USD 6,917/MT, while China's index increased by 7.44% to approximately USD 6,845.33/MT. Germany also experienced upward pressure from freight, insurance, container imbalances, and longer transit times.

For the coming quarters, freight rates, shipping reliability, and pharmaceutical procurement activity will remain important variables to monitor. Buyers can improve cost visibility and supply-chain resilience through careful supplier evaluation, landed-cost comparisons, and disciplined inventory planning. These measures will help pharmaceutical manufacturers respond more effectively to changes in the Guaifenesin Price Trend throughout 2026.

About Us:

Welcome to ChemAnalyst, a next–generation platform for chemical and petrochemical intelligence where innovation meets practical insight. Recognized as “Product Innovator of the Year 2023” and ranked among the “Top 100 Digital Procurement Solutions Companies,” we lead the digital transformation of the global chemical sector. Our online platform helps companies handle price volatility with structured analysis, real-time pricing, and reliable news and deal updates from across the world. Tracking over 500 chemical prices in more than 40 countries becomes simple and efficient with us.

Contact Us:

Address:

420 Lexington Avenue, Suite 300 New York, NY 10170 United States

Phone: +1 332 258 6602

Email: [email protected]

Website: https://www.chemanalyst.com/

LinkedIn: https://www.linkedin.com/company/chemanalyst/

Facebook: https://www.facebook.com/ChemAnalysts/

Twitter: https://x.com/chemanalysts

YouTube: https://www.youtube.com/@chemanalyst

Instagram: https://www.instagram.com/chemanalyst_